Sanofi Acquires Vigil Neuroscience for $470 Million to Advance Neurodegenerative Disease Treatments

Sanofi has finalized an agreement to acquire Vigil Neuroscience for $470 million. This move comes nearly a year after Sanofi made an initial investment of $40 million in the company. The acquisition is part of Sanofi’s broader efforts to expand its presence in neuroscience, particularly in the development of treatments for neurodegenerative diseases such as Alzheimer’s.

Vigil Neuroscience specializes in developing therapies targeting microglia, immune cells found in the central nervous system that play a role in neuroinflammation and neurodegeneration. The company’s research focuses on addressing conditions linked to microglial dysfunction, including rare genetic disorders and more common diseases like Alzheimer’s. Sanofi’s decision to acquire Vigil follows its earlier financial commitment and reflects ongoing interest in advancing therapeutic options within this field.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 22, 2025

Related posts:

DrugPatentWatch Guide Explores Fixed-Fee and Cost-Plus CDMO Pricing Models DrugPatentWatch: Generic Drug Stability Testing Key to Freedom to Operate Analysis for Biopharmaceuticals Generic Drug Approval Hinges on Stability Testing: Controlled Environments and Packaging Key, Says DrugPatentWatch Analysis Drug Patent Watch: Biosimilar Supply Chain Issues Lead to Higher Costs and Access Delays for Patients and Payers

Author

Mark Chiang